Global Supply & Trade
Pharmaceutical supply chains are inherently global. Medicines consumed in Canada often rely on ingredients sourced internationally, are manufactured across multiple jurisdictions, and move through highly regulated distribution networks before reaching patients.
Protecting Canada’s Drug Supply in a Global Market
In this interconnected system, policy decisions made in one country can have ripple effects far beyond its borders. Unlike larger markets, Canada’s system is calibrated to meet domestic demand—not global re-export. When external demand is introduced, especially from a significantly larger market, it places pressure on a system that is not designed for surplus capacity.
U.S. Importation
Efforts in the United States to import prescription drugs from Canada are driven by a need to address pricing disparities. These initiatives aim to leverage Canada’s lower drug prices by redirecting supply across borders; however, they introduce real and immediate risks to Canada’s carefully balanced pharmaceutical supply chain. At Vital, we represent the organizations that move medicines safely, efficiently, and reliably across Canada. We believe any policy enabling large-scale U.S. importation must be evaluated through one critical lens: its impact on Canadian patients and system stability.
Why This Matters for Canada
Canada represents a small, tightly managed pharmaceutical market—not a surplus supply for international demand. From a global supply chain perspective, U.S. importation raises several concerns:
- Demand Imbalance
- The U.S. market is nearly ten times larger than Canada’s. Even limited importation could significantly alter supply-demand dynamics.
- Supply Chain Strain
- Manufacturing and distribution networks are optimized for forecasted demand. Sudden increases—especially externally driven—can disrupt procurement, inventory planning, and delivery timelines.
- Increased Shortage Risk
- Canada already operates within a constrained supply environment. Additional demand pressures increase the likelihood and severity of drug shortages.
- Regulatory Tension
- Canada’s regulatory framework prioritizes domestic access. Export-driven demand introduces friction between international trade and national healthcare obligations.
Health Canada has already taken steps to prevent exports that could worsen shortages, prohibiting distribution if it risks domestic supply stability.
The Government of Canada has also reaffirmed its commitment to protecting access to medicines for Canadians first, even as discussions continue in the United States.
Canada’s pharmaceutical supply chain is designed for predictable demand, regulated pricing, and controlled distribution channels. Disrupting this balance creates risks that extend beyond logistics to patient care outcomes.
Vital’s Perspective
Vital views U.S. importation through a global lens. We support:
- Sustainable, coordinated supply chain practices across borders
- Policies that respect the capacity limits of smaller markets
- Safeguards that protect patient access within Canada
Global challenges require global solutions—but not at the expense of system stability.
Vital supports policies that prioritize uninterrupted access to medications, maintain supply chain integrity, and ensure cross-border trade does not destabilize domestic supply.
We believe Canada must not become a backfill solution for systemic pricing challenges in other markets.
Looking Ahead
As cross-border pharmaceutical policies evolve, it is essential to recognize that supply chains do not operate in isolation.
Effective solutions must reflect the realities of global manufacturing and distribution; consider downstream impacts on all participating markets; and balance affordability with supply security.
Vital will continue to advocate for resilient, transparent, and globally informed supply chain policies that protect Canadians while supporting international collaboration.
Cross-border collaboration is essential, but it must be grounded in:
- Data-driven impact assessments
- Strong regulatory safeguards
- Ongoing dialogue between governments and industry stakeholders
Vital will continue to advocate for policies that protect the resilience, reliability, and sustainability of Canada’s pharmaceutical supply chain.
